Company
Alimera Sciences, Inc.
Headquarters: Alpharetta, GA, United States
Founded: 2003
Employees: 145
CEO: Mr. Richard S. Eiswirth Jr.
Market Cap
$290.8 Million
USD as of July 1, 2024
Alimera Sciences, Inc. Categories
United States Healthcare Drug Manufacturers—Specialty & GenericUnited States Healthcare United States Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Alimera Sciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ALIM wb_incandescent
Stock: FSX: ASZ1 wb_incandescent
Product & Services
Pharmaceuticals
Key People
Rick Eiswirth, (President, CEO)
Financials
Revenue: $54.1 Million(2019)